The Regents of the University of Michigan;Millendo Therapeutics, Inc.
发明人:
Hammer, Gary,Kerppola, Tom,Kerppola, Raili
申请号：
AU2017261632
公开号：
AU2017261632A1
申请日:
2017.11.17
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
#$%^&*AU2017261632A120171207.pdf#####ll: szp Interwovn NRPortbl DCC SZP 16024930 _.docx-I7 /t2017 ABSTRACT Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1methylethyl)phenyl)-N'-((1 -(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
